Please login to the form below
Pfizer’s Paxlovid receives positive opinion from CHMP
If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU
Moderna begins phase 2 trial of Omicron-specific booster
The study will include two groups, with approximately 300 people in each group
FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments
The company confirmed that six other phase 2 trials would go ahead as previously planned
Janssen’s Tremfya receives positive results for active psoriatic arthritis
The drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies
Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine
The clinical trial involves adults aged 18 to 55 who received an Omicron-based vaccine candidate as part of a two-dose primary series, as well as a booster
FDA restricts use of certain antibody treatments for COVID-19
The restrictions reflect recent data that shows these antibodies are not effective against the Omicron variant
FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies
The review of Evrysdi has been developed for pre-symptomatic babies under two months old with spinal muscular atrophy
Ipsen’s Sohonos approved by Health Canada
The drug is the first approved treatment for individuals with fibrodysplasia ossificans progressiva
Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
The FDA also issued an EUA for the treatment to include non-hospitalised paediatric patients 12 years and under who are at high risk of disease progression
Q&A: Claire Gillis
PME interviews VMLY&Rx's CEO
-
Q&A: Sarah GordonPME interviews Virgo Health's head of health
-
Q&A: Amar UrhekarPME interviews Ashfield Health's Global President
-
SMC approves Parkinson’s disease treatment OngentysThe once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland
-
PM announces plans to lift England’s COVID-19 restrictions Following the announcement, England is set to remove its ‘Plan B’ COVID-19 restrictions over the next week
-
Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatmentThe study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma
-
GSK appoint Tony Wood as chief scientific officerWood’s appointment will follow the exit of Dr Hal Barron, effective from August 2022
-
Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial resultsThe trial confirms the potential benefit of targeting inflammation in prurigo nodularis
-
AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patientsThe phase 3 trial results for patients diagnosed with first-line unresectable liver cancer showed a 31% survival rate after three years
-
Almirall and IRB Barcelona announce new research collaborationThe two companies will work together to discover new therapies for chronic skin diseases
Latest appointments
-
Anthem PR appoints new managing director Rebecca Fergusson
Fergusson previously held senior leadership positions at Mind + Matter and Red Health
-
Andy Black joins Lucid Group as non-executive chairmanBlack is co-founder of Kinapse and a Professor of Practice at King’s College London
-
Christianna Gorin is appointed Health Practice Lead and Chief Strategy Officer, VMLY&R HealthWith origins in health consultancy and insight, Gorin has spent over 20 years in healthcare
-
OPEN Health announces new comms CEO Margot HannahHannah joined OPEN Health in 2011
-
David Hunt launches independent agency The ConsideredThe team includes Professor Shafi Ahmed, Aurora Archer, Jane Kidd and CCO Pete Armstrong
COVID-19 Updates and Daily News
Featured jobs
-
Head of Copy
-
£ competitive
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
-
Account Manager
-
Competitive salary with bonus and benefits
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Home or away: where next for pharmaceutical symposia?
- Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
- FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies
- FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- Pfizer’s Paxlovid receives positive opinion from CHMP
- Moderna begins phase 2 trial of Omicron-specific booster
- Expanding Access to High-Quality Healthcare
- FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments
- Janssen’s Tremfya receives positive results for active psoriatic arthritis
- ARISE - a strategic healthcare communication planning process from Bedrock
- Why pharma must get smart in its approach to customer engagement
- Pfizer's 2021 revenue predictions soar to $82bn
- J&J taps TARIS Biomedical for novel bladder cancer technology
- Anthem PR appoints new managing director Rebecca Fergusson
- Current and future trends for developing digital medical communications
- GSK appoint Tony Wood as chief scientific officer
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Personalised medicine: driving a need for greater diversity in clinical trials
- Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
